Literature DB >> 3131431

In vivo administration of recombinant IFN-gamma induces macrophage activation, and prevents acute disease, immune suppression, and death in experimental Trypanosoma cruzi infections.

S G Reed1.   

Abstract

Recombinant murine IFN-gamma (rMu-IFN-gamma) was demonstrated to be a potent in vivo activator of mouse peritoneal macrophages to kill Trypanosoma cruzi in vitro and to be capable of conferring protection against death from acute T. cruzi infection. Following i.p. injections of rMu-IFN-gamma, resident peritoneal macrophages were cultured and infected with T. cruzi in vitro. Numbers of intracellular parasites were determined at different times thereafter. Ten or 100 micrograms (1 microgram = 6.5 X 10(5) U) of Mu-IFN-gamma, injected both 24 and 4 h before macrophage harvest, induced up to 99% inhibition of T. cruzi. One microgram of rMu-IFN-gamma was not effective under these conditions. In vitro inhibition of T. cruzi by peritoneal macrophages occurred by 24 h after infection and continued until at least 120 h after infection. There were no significant differences in initial parasite uptake by macrophages from IFN-gamma-treated or control mice, indicating that the rMu-IFN-gamma induced parasite killing. One i.p. dose of 10 micrograms was as effective as two doses if the single injection was given 24 h before macrophage harvest. In subsequent experiments, mice were given multiple injections of 10 micrograms rMu-IFN-gamma beginning 24 h before or 2 h after infection with virulent T. cruzi. Mice treated with rMu-IFN-gamma had significantly lower parasitemias and decreased morbidity compared with control mice. Proliferative responses to Con A and antibody responses to SRBC were not significantly lowered in IFN-gamma-treated mice, in contrast to untreated infected controls. All of the IFN-gamma-treated mice survived acute T. cruzi infection, whereas 100% of saline-treated infected mice died. It was demonstrated in this study that rMu-IFN-gamma activated mouse macrophages in vivo to kill T. cruzi and that rMu-IFN-gamma significantly reduced morbidity and immune suppression, and eliminated mortality resulting from acute infection with this parasite.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3131431

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  75 in total

1.  Stage-dependent role of nitric oxide in control of Trypanosoma cruzi infection.

Authors:  M Saeftel; B Fleischer; A Hoerauf
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

2.  Replication of Toxoplasma gondii, but not Trypanosoma cruzi, is regulated in human fibroblasts activated with gamma interferon: requirement of a functional JAK/STAT pathway.

Authors:  I P Cerávolo; A C Chaves; C A Bonjardim; D Sibley; A J Romanha; R T Gazzinelli
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  In vitro responses to Leishmania antigens by lymphocytes from patients with leishmaniasis or Chagas' disease.

Authors:  S G Reed; E M Carvalho; C H Sherbert; D P Sampaio; D M Russo; O Bacelar; D L Pihl; J M Scott; A Barral; K H Grabstein
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

4.  Humoral and cellular immune responses in BALB/c and C57BL/6 mice immunized with cytoplasmic (CRA) and flagellar (FRA) recombinant repetitive antigens, in acute experimental Trypanosoma cruzi infection.

Authors:  Valéria R A Pereira; Virginia M B Lorena; Mineo Nakazawa; Carlos F Luna; Edimilson D Silva; Antonio G P Ferreira; Marco Aurélio Krieger; Samuel Goldenberg; Milena B P Soares; Eridan M Coutinho; Rodrigo Correa-Oliveira; Yara M Gomes
Journal:  Parasitol Res       Date:  2005-04-27       Impact factor: 2.289

5.  Intracellular growth of Trypanosoma cruzi in cardiac myocytes is inhibited by cytokine-induced nitric oxide release.

Authors:  Laura Edith Fichera; Maria Cecilia Albareda; Susana Adriana Laucella; Miriam Postan
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

Review 6.  Modulation of immune response in experimental Chagas disease.

Authors:  Beatriz Basso
Journal:  World J Exp Med       Date:  2013-02-20

7.  Transforming growth factor beta as a virulence mechanism for Leishmania braziliensis.

Authors:  A Barral; M Barral-Netto; E C Yong; C E Brownell; D R Twardzik; S G Reed
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

8.  Tumor necrosis factor alpha mediates resistance to Trypanosoma cruzi infection in mice by inducing nitric oxide production in infected gamma interferon-activated macrophages.

Authors:  J S Silva; G N Vespa; M A Cardoso; J C Aliberti; F Q Cunha
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

9.  Trypanosoma cruzi amastigote adhesion to macrophages is facilitated by the mannose receptor.

Authors:  S Kahn; M Wleklinski; A Aruffo; A Farr; D Coder; M Kahn
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

10.  TCR independent suppression of CD8(+) T cell cytokine production mediated by IFNγ in vivo.

Authors:  Martin P Hosking; Claudia T Flynn; J Lindsay Whitton
Journal:  Virology       Date:  2016-08-24       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.